Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population

Annals of the New York Academy of Sciences

Volumn 1108, Issue , 2007, Pages 96-103

  Cederholm, Anna ^a   Frostegård, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Annexin A5; Atherothrombosis; Cardiovascular disease; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR; SULFATIDE; THROMBOPLASTIN; UROKINASE;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE INTERACTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; IMMUNITY; NONHUMAN; PHYSIOLOGY; PROTEIN BINDING; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALIA;

EID: 34948896971     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1422.011     Document Type: Conference Paper

References (55)

1. COULL, B.M. et al. 2002. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology 59: 13-22.
2. PUMA, J.A. & M.H. SKETCH, JR. 2000. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. J. Am. Osteopath. Assoc. 100: S8-S12.
3. THIAGARAJAN, P. 2002. New targets for antithrombotic drugs. Am. J. Cardiovasc. Drugs 2: 227-235.
4. RAYNAL, P. & H.B. POLLARD. 1994. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim. Biophys. Acta 1197: 63-93.
5. GERKE, V., C.E. CREUTZ & S.E. MOSS. 2005. Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell. Biol. 6: 449-461.
6. TAIT, J.F. et al. 1991. Chromosomal localization of the human gene for annexin V (placental anticoagulant protein I) to 4q26-q28. Cytogenet. Cell. Genet. 57: 187-192.
7. GONZALEZ-CONEJERO, R. et al. 2002. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood 100: 2081-2086.
8. MATSUDA, R. et al. 2000. Measurement of urinary annexin V by ELISA and its significance as a new urinary-marker of kidney disease. Clin. Chim. Acta 298: 29-43.
9. VERMES, I. et al. 1999. Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause. Mov. Disord. 14: 1008-1010.
10. HUBER, R., J. ROMISCH & E. P. PAQUES. 1990. The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes. EMBO J. 9: 3867-3874.
11. REUTELINGSPERGER, C.P., G. HORNSTRA & H.C. HEMKER. 1985. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur. J. Biochem. 151: 625-629.
12. FUNAKOSHI, T. et al. 1987. Human placental anticoagulant protein: isolation and characterization. Biochemistry 26: 5572-5578.
13. WANG, X. et al. 1999. Annexin V is critical in the maintenance of murine placental integrity. Am. J. Obstet. Gynecol. 180: 1008-1016.
14. RAND, J.H. et al. 2006. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am. J. Obstet. Gynecol. 194: 182-188.
15. BRACHVOGEL, B. et al. 2003. Annexin A5 is not essential for skeletal development. Mol. Cell. Biol. 23: 2907-2913.
16. HOFFMAN, M. 2003. Remodeling the blood coagulation cascade. J. Thromb. Thrombolysis 16: 17-20.
17. LENTZ, B.R. 2003. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog. Lipid Res. 42: 423-438.
18. EILERTSEN, K.E. & B. OSTERUD. 2004. Tissue factor: (patho)physiology and cellular biology. Blood Coagul. Fibrinolysis 15: 521-538.
19. COMFURIUS, P. et al. 1994. Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry 33: 10319-10324.
20. TAIT, J.F. & D. GIBSON. 1992. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch. Biochem. Biophys. 298: 187-191.
21. ANDREE, H.A. et al. 1992. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J. Biol. Chem. 267: 17907-17912.
22. RAVASSA, S. et al. 2005. Annexin A5 down-regulates surface expression of tissue factor: a novel mechanism of regulating the membrane receptor repertoir. J. Biol. Chem. 280: 6028-6035.
23. IDA, M. et al. 2004. Human annexin V binds to sulfatide: contribution to regulation of blood coagulation. J. Biochem. (Tokyo) 135: 583-588.
24. CAPILA, I. et al. 1999. Interaction of heparin with annexin V. FEBS Lett. 446: 327-330.
25. JU, C.W. et al. 2004. A study of human annexin V derivative: its effects of anticoagulation and antithrombosis. Zhonghua Xue Ye Xue Za Zhi. 25: 540-543.
26. HUANG, X. et al. 2006. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood 107: 980-986.
27. KOOPMAN, G. et al. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84: 1415-1420.
28. BOERSMA, H.H. et al. 2005. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 46: 2035-2050.
29. HANSSON, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
30. ROSS, R. 1999. Atherosclerosis is an inflammatory disease. Am. Heart J. 138: S419-S420.
31. ESMON, C.T. 2003. Coagulation and inflammation. J. Endotoxin Res. 9: 192-198.
32. AIKAWA, M. & P. LIBBY. 2004. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc. Pathol. 13: 125-138.
33. ANANYEVA, N.M. et al. 2002. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood 99: 4475-4485.
34. TOSCHI, V. et al. 1997. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95: 594-599.
35. WILCOX, J.N. et al. 1989. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86: 2839-2843.
36. CEDERHOLM, A. et al. 2005. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 25: 198-203.
37. FADOK, V.A. et al. 1998. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 5: 551-562.
38. KENIS, H. et al. 2006. Annexin A5 inhibits engulfment through internalization of PS-expressing cell membrane patches. Exp. Cell. Res. 312: 719-726.
39. CEDERHOLM, A. 2006. Novel immunological mechanisms and factors in systemic lupus erythematosus-related cardiovascular disease, Karolinska Institutet. Stockholm.
40. STACH, C.M. et al. 2000. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ. 7: 911-915.
41. VAN RYN-MCKENNA, J. et al. 1993. The effects of heparin and annexin V on fibrin accretion after injury in the jugular veins of rabbits. Thromb. Haemost. 69: 227-230.
42. THIAGARAJAN, P. & C.R. BENEDICT. 1997. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 96: 2339-2347.
43. SARDA-MANTEL, L. et al. 2006. 99mTc-annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26: 2153-2159.
44. FROSTEGARD, J. 2005. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25: 1776-1785.
45. SHOENFELD, Y. et al. 2005. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: 3337-3347.
46. DEL CONDE, I. et al. 2005. Tissue factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106: 1604-1611.
47. BREY, R.L. et al. 2001. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 32: 1701-1706.
48. SVENUNGSSON, E. et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887-1893.
49. UROWITZ, M.B. et al. 1976. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60: 221-225.
50. MANZI, S. et al. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145: 408-415.
51. RAND, J.H. et al. 2004. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 104: 2783-2790.
52. HANLY, J.G., S. A. SMITH & D. ANDERSON. 2003. Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis. J. Rheumatol. 30: 1990-1993.
53. RAND, J.H. et al. 1997. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am. J. Obstet. Gynecol. 177: 918-923.
54. VAN TITS, L. et al. 2005. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 25: 717-722.
55. LEON, C. et al. 2006. Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. J. Immunol. 176: 5934-5942.